CD274 and hepatocellular carcinoma: In May 2020, the programmed cell death 1 ligand (PD-L1) antibody atelizumab combined with the target drug bevacizumab was introduced as the first-line treatment for advanced HCC, which reduced the risk of death in these patients by 42% compared with the traditional first-line treatment using sorafenib, thus bringing new hope to the long-term survival of patients with HCC (Casak et al., 2021).